MY116150A - Use of sibutramine analogues to prevent the development of diabetes - Google Patents

Use of sibutramine analogues to prevent the development of diabetes

Info

Publication number
MY116150A
MY116150A MYPI97004383A MYPI19974383A MY116150A MY 116150 A MY116150 A MY 116150A MY PI97004383 A MYPI97004383 A MY PI97004383A MY PI19974383 A MYPI19974383 A MY PI19974383A MY 116150 A MY116150 A MY 116150A
Authority
MY
Malaysia
Prior art keywords
diabetes
development
prevent
formula
sibutramine
Prior art date
Application number
MYPI97004383A
Other languages
English (en)
Inventor
James Bailey Clifford
Christine Jackson Helen
Brian Jones Robert
Original Assignee
Abbott Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Gmbh & Co Kg filed Critical Abbott Gmbh & Co Kg
Publication of MY116150A publication Critical patent/MY116150A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Electrotherapy Devices (AREA)
MYPI97004383A 1996-09-21 1997-09-20 Use of sibutramine analogues to prevent the development of diabetes MY116150A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9619757.9A GB9619757D0 (en) 1996-09-21 1996-09-21 Chemical process

Publications (1)

Publication Number Publication Date
MY116150A true MY116150A (en) 2003-11-28

Family

ID=10800326

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI97004383A MY116150A (en) 1996-09-21 1997-09-20 Use of sibutramine analogues to prevent the development of diabetes

Country Status (26)

Country Link
US (3) US6174925B1 (https=)
EP (1) EP0927028A1 (https=)
JP (1) JP2001503737A (https=)
KR (1) KR20000048501A (https=)
CN (1) CN1237905A (https=)
AU (1) AU724488B2 (https=)
BG (1) BG64473B1 (https=)
BR (1) BR9711517A (https=)
CA (1) CA2266401C (https=)
CZ (1) CZ93699A3 (https=)
GB (1) GB9619757D0 (https=)
HR (1) HRP970505A2 (https=)
HU (1) HUP9904026A3 (https=)
ID (1) ID18320A (https=)
IL (1) IL128850A (https=)
MY (1) MY116150A (https=)
NO (1) NO991358D0 (https=)
NZ (1) NZ334580A (https=)
PL (1) PL332305A1 (https=)
RU (1) RU2245709C2 (https=)
SK (1) SK31999A3 (https=)
TR (1) TR199900618T2 (https=)
TW (1) TW580385B (https=)
UA (1) UA64726C2 (https=)
WO (1) WO1998011884A1 (https=)
ZA (1) ZA978450B (https=)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9619757D0 (en) * 1996-09-21 1996-11-06 Knoll Ag Chemical process
JP2000080047A (ja) * 1998-06-30 2000-03-21 Takeda Chem Ind Ltd 医 薬
AR019727A1 (es) * 1998-06-30 2002-03-13 Takeda Chemical Industries Ltd Composicion farmaceutica
US6339106B1 (en) 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
US6331571B1 (en) 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
US6974838B2 (en) * 1998-08-24 2005-12-13 Sepracor Inc. Methods of treating or preventing pain using sibutramine metabolites
US6476078B2 (en) * 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
CZ20011629A3 (cs) * 1998-11-12 2001-12-12 Smithkline Beecham Plc Farmaceutický prostředek pro upravené uvolňování senzitizéru inzulínu a jiných antidiabetických přípravků
AR023699A1 (es) * 1998-11-12 2002-09-04 Smithkline Beecham Corp Una composicion farmaceutica que comprende un estabilizador de insulina y un procedimiento para preparar una composicion farmaceutica
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
US6696495B2 (en) 1998-12-02 2004-02-24 Snowden Pharmaceuticals, Llc Treatment of disorders secondary to organic impairments
US6323242B1 (en) 1998-12-02 2001-11-27 Peter Sterling Mueller Treatment of disorders secondary to organic impairments
US6552087B1 (en) 1999-03-19 2003-04-22 Abbott Gmbh & Co. Kg Therapeutic agent comprising (+)-sibutramine
US6680344B1 (en) 1999-06-01 2004-01-20 The University Of Texas Southwestern Medical Center Method of treating hair loss using diphenylmethane derivatives
WO2000072810A1 (en) 1999-06-01 2000-12-07 The University Of Texas Southwestern Medical Center Method of treating hair loss using sulfonyl thyromimetic compounds
US6723717B1 (en) 1999-06-01 2004-04-20 The University Of Texas Southwestern Medical Center Sulfur-containing thyroxane derivatives and their use as hair growth promotors
GB9914744D0 (en) * 1999-06-24 1999-08-25 Knoll Ag Therapeutic agents
US6399826B1 (en) 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
WO2002083631A1 (en) 2001-04-13 2002-10-24 Sepracor Inc. Methods of preparing didesmethylsibutramine and other sibutramine derivatives
US8911781B2 (en) 2002-06-17 2014-12-16 Inventia Healthcare Private Limited Process of manufacture of novel drug delivery system: multilayer tablet composition of thiazolidinedione and biguanides
NZ538966A (en) * 2002-10-05 2006-11-30 Hanmi Pharm Pharmaceutical composition comprising crystalline sibutramine methanesulfonate hemihydrate
US20050131074A1 (en) * 2003-08-04 2005-06-16 Beckman Kristen M. Methods for treating metabolic syndrome
PE20050335A1 (es) * 2003-08-07 2005-06-01 Sb Pharmco Inc Forma de dosificacion oral que comprende 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidin-2,4-diona y procedimiento para la preparacion
GB0318824D0 (en) * 2003-08-11 2003-09-10 Glaxo Group Ltd Novel composition
CA2540225C (en) * 2003-10-31 2012-03-06 Takeda Pharmaceutical Company Limited Solid preparation of pioglitazone, glimepiride and a polyoxyethylene sorbitan fatty acid ester
KR100627687B1 (ko) * 2005-04-20 2006-09-25 주식회사 씨티씨바이오 시부트라민 유리염기 함유 조성물 및 이의 제조방법
BRPI0706365A2 (pt) 2006-01-06 2011-03-22 Sepracor Inc Cicloalquilaminas como inibidores da recaptação de monoamina
CA2663254C (en) 2006-09-15 2016-04-19 Reviva Pharmaceuticals, Inc. Synthesis, methods of using, and compositions of cycloalkylmethylamines
KR100812538B1 (ko) * 2006-10-23 2008-03-11 한올제약주식회사 약물 제어방출형 메트포르민-글리메피리드 복합제제
KR20080046601A (ko) * 2006-11-22 2008-05-27 에스케이케미칼주식회사 보관안정성이 우수한 시부트라민 함유 포접복합체
DK2118123T3 (en) 2007-01-31 2016-01-25 Dana Farber Cancer Inst Inc Stabilized p53 peptides and uses thereof
US8592377B2 (en) 2007-03-28 2013-11-26 President And Fellows Of Harvard College Stitched polypeptides
US9237864B2 (en) 2009-07-02 2016-01-19 Dexcom, Inc. Analyte sensors and methods of manufacturing same
WO2012003501A2 (en) 2010-07-02 2012-01-05 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives
ES2711526T3 (es) 2010-08-13 2019-05-06 Aileron Therapeutics Inc Macrociclos peptidomiméticos
TW201806968A (zh) 2011-10-18 2018-03-01 艾利倫治療公司 擬肽巨環化合物
US9238625B2 (en) 2011-12-30 2016-01-19 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using phenylcycloalkylmethylamine derivatives
BR112014020103A2 (pt) 2012-02-15 2018-10-09 Aileron Therapeutics, Inc. macrociclos peptidomiméticos
EP2819688A4 (en) 2012-02-15 2015-10-28 Aileron Therapeutics Inc TRIAZOL AND THIOETHER-COUPLED PEPTIDOMIMETIC MACROCYCLES
WO2014071241A1 (en) 2012-11-01 2014-05-08 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
EP3197478A4 (en) 2014-09-24 2018-05-30 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
WO2016154058A1 (en) 2015-03-20 2016-09-29 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52768B1 (en) * 1981-04-06 1988-02-17 Boots Co Ltd 1-arylcyclobutylalkylamine compounds useful as therapeutic agents
GB8531071D0 (en) * 1985-12-17 1986-01-29 Boots Co Plc Therapeutic compound
GB8704777D0 (en) * 1987-02-28 1987-04-01 Boots Co Plc Medical treatment
JP2675573B2 (ja) * 1988-03-31 1997-11-12 科研製薬株式会社 脳機能改善剤
IE61928B1 (en) * 1988-11-29 1994-11-30 Boots Co Plc Treatment of obesity
WO1995010292A1 (en) 1993-10-14 1995-04-20 Biomedica California, Inc. Diabetes treatment and prophylaxis
US5459164A (en) * 1994-02-03 1995-10-17 Boots Pharmaceuticals, Inc. Medical treatment
GB9619757D0 (en) * 1996-09-21 1996-11-06 Knoll Ag Chemical process

Also Published As

Publication number Publication date
IL128850A0 (en) 2000-01-31
NZ334580A (en) 2000-09-29
NO991358L (no) 1999-03-19
HUP9904026A3 (en) 2000-07-28
CN1237905A (zh) 1999-12-08
KR20000048501A (ko) 2000-07-25
JP2001503737A (ja) 2001-03-21
PL332305A1 (en) 1999-08-30
GB9619757D0 (en) 1996-11-06
BR9711517A (pt) 1999-08-24
RU2245709C2 (ru) 2005-02-10
BG103277A (en) 2000-01-31
SK31999A3 (en) 1999-12-10
AU4774097A (en) 1998-04-14
IL128850A (en) 2003-07-31
ZA978450B (en) 1999-03-19
WO1998011884A1 (en) 1998-03-26
TR199900618T2 (xx) 1999-06-21
ID18320A (id) 1998-03-26
CA2266401C (en) 2007-01-30
HUP9904026A2 (hu) 2000-05-28
AU724488B2 (en) 2000-09-21
CZ93699A3 (cs) 1999-08-11
US6174925B1 (en) 2001-01-16
UA64726C2 (uk) 2004-03-15
US6617360B1 (en) 2003-09-09
NO991358D0 (no) 1999-03-19
HRP970505A2 (en) 1998-08-31
TW580385B (en) 2004-03-21
BG64473B1 (bg) 2005-04-30
US20040077730A1 (en) 2004-04-22
CA2266401A1 (en) 1998-03-26
EP0927028A1 (en) 1999-07-07

Similar Documents

Publication Publication Date Title
MY116150A (en) Use of sibutramine analogues to prevent the development of diabetes
EP0814788A4 (en) IMPROVEMENT OF GLUCOSE TOLERANCE
IE863102L (en) N,n,1,3-tetrasubstituted butylamine derivative.
CA2003524A1 (en) Treatment of obesity
CA2367666A1 (en) Method of treating eating disorders
SG127714A1 (en) Method of treating metabolic disorders, especiallydiabetes, or a disease or condition associated wi th diabetes
DK0973511T3 (da) Anvendelse af sibutraminanaloger til at sænke lipidniveauer
IL128851A (en) Pharmaceutical composition for lowering the uric acid level in the human body
KR920016089A (ko) 제i형 당뇨병의 치료방법
CR6640A (es) Nuevos derivados de tiazolidindiona como agentes antidiabeticos
SI1169029T1 (sl) Uporaba sibutramina ali njegova derivata za zdravljenje motenj med spanjem
HK1045254A1 (zh) 降低血小板黏性的处理方法
MXPA01009461A (es) Tratamiento de osteoartritis.
CA2388176A1 (en) Therapeutic agent for eating disorders
MXPA01009468A (es) Tratamiento de hipertension pulmonar.
MXPA01009465A (es) Perdida de peso despues del embarazo.
BG106000A (en) Treatment of hiatial hernia
MXPA02003516A (es) Clorihidrato de n-[3-[[2-(3,4-dimetoxifenil)etil]amino[propil]-4-nitrobenzamida polimorfico.
WO2000056316A8 (en) Treatment of gallstones
Jun-Yi An Ever Exploring Work For the Study in Modern History of China--A Review" About The Book" A Chronicle of Chinese Famine in Modern Time
TH52365A (th) การรักษาทางการแพทย์